Regcon Holdings Company Profile
✉ Email this page to a colleague
What is the competitive landscape for REGCON HOLDINGS
REGCON HOLDINGS has forty-seven approved drugs.
Drugs and US Patents for Regcon Holdings
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regcon Holdings | FEBUXOSTAT | febuxostat | TABLET;ORAL | 210292-002 | Dec 30, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | BACLOFEN | baclofen | TABLET;ORAL | 214114-001 | Jul 16, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | ACETYLCYSTEINE | acetylcysteine | INJECTABLE;INTRAVENOUS | 215620-001 | Feb 23, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 216568-002 | Mar 30, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | ALLOPURINOL | allopurinol | TABLET;ORAL | 204467-003 | May 22, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | NADOLOL | nadolol | TABLET;ORAL | 210955-002 | Jul 23, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

